Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had ...

Judge Rebecca A. Sanders, chair of the Workers Compensation Appeals Board of the Kansas Department of Labor, Topeka, is the ...

“Marketresearch.biz reports that the Ataxia market was valued at USD 11,558.3 million in 2023. It is expected to reach USD 20,778.5 million by 2033, with a CAGR of 6.20% during the forecast period ...

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from ...

Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data ...

Data from the DDRiver™ Clinical Trials program highlight the potential of the investigational oral ataxia telangiectasia and ...

The Movement festival kicks off today at Hart Plaza in Detroit. Here's the opening day artist schedule, listed by times. 2 ...

(RTTNews) - Larimar Therapeutics, Inc. (LRMR) Tuesday announced that FDA has removed the partial clinical hold placed on its nomlabofusp or CTI-1601, a clinical program targeting treatment of patients ...

Camila Colin, 17, attended the groundbreaking ceremony for Keaton’s House: Paul Paletta Children’s Hospice in Dundas, Ont., ...

BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced this week that the U.S. Food and Drug Administration ...

Larimar Therapeutics’ stock $LRMR shot up by as much as 20% after announcing Monday that the FDA had lifted its partial ...